SEOUL, Jan. 12 (Korea Bizwire) — South Korea’s drug safety agency on Wednesday authorized the use of U.S.-based biotechnology company Novavax Inc.’s COVID-19 vaccine. The protein-based vaccine, Nuvaxovid, marks the fifth COVID-19 vaccine to get approval for use here, following the ones by British-Swedish pharmaceutical giant AstraZeneca and Oxford University, Pfizer Inc., Johnson & Johnson [...]
SEOUL, Dec. 24 (Korea Bizwire) — SK Bioscience Co., a vaccine unit of South Korea’s SK Group, said Friday it has extended an agreement to manufacture a component of the U.S.-based biotechnology company Novavax Inc.’s COVID-19 vaccine by one more year. Under the extended agreement, SK Bioscience will reserve additional manufacturing capacity to produce antigen, [...]
GAITHERSBURG, Md., Feb. 22 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously reported positive interim [...]
GAITHERSBURG, Md., Feb. 18 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance (Gavi), to provide 1.1 billion cumulative doses of NVX-CoV2373, Novavax’ recombinant protein-based COVID-19 vaccine candidate, for the COVAX Facility. The vaccine doses [...]
GAITHERSBURG, Md., Feb. 15 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement. In addition to the already existing manufacturing arrangement, SK Bioscience has obtained a license to manufacture and [...]
GAITHERSBURG, Md., Feb. 4 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its pivotal Phase 3 trials in [...]
GAITHERSBURG, Md., Jan. 28 (Korea Biziwre) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). The study assessed [...]
GAITHERSBURG, Md., Jan. 15 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Henrietta Ukwu, M.D., FACP, FRAPS, to the position of Senior Vice President, Chief Regulatory and Quality Officer. In this newly created role, Dr. Ukwu will lead global regulatory [...]
SEOUL, Jan. 12 (Korea Bizwire) — South Korea is close to striking a deal to purchase COVID-19 vaccines for 10 million people from U.S. drugmaker Novavax, according to informed sources Tuesday. The Seoul government has been negotiating with Novavax to secure its vaccines as early as in the second quarter of this year, sources with [...]
GAITHERSBURG, Md., Jan. 7 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. This follows an agreement in principle that was [...]